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ABSTRACT Generating durable humoral immunity through vaccination depends
upon effective interactions of follicular helper T (Tfh) cells with germinal center
(GC) B cells. Th1 polarization of Tfh cells is an important process shaping the suc-
cess of Tfh-GC B cell interactions by influencing costimulatory and cytokine-
dependent Tfh help to B cells. However, the question remains as to whether
adjuvant-dependent modulation of Tfh cells enhances HIV-1 vaccine-induced an-
tienvelope (anti-Env) antibody responses. We investigated whether an HIV-1 vac-
cine platform designed to increase the number of Th1-polarized Tfh cells enhances
the magnitude and quality of anti-Env antibodies. Utilizing a novel interferon-
induced protein 10 (IP-10)-adjuvanted HIV-1 DNA prime followed by a monophos-
phoryl lipid A and QS-21 (MPLAQS-21)-adjuvanted Env protein boost (DIP-10 PALFQ)
in macaques, we observed higher anti-Env serum IgG titers with greater cross-clade
reactivity, specificity for V1V2, and effector functions than in macaques primed
with DNA lacking IP-10 and boosted with MPLA-plus-alum-adjuvanted Env pro-
tein (DPALFA) The DIP-10 PALFQ vaccine regimen elicited higher anti-Env IgG1 and
lower IgG4 antibody levels in serum, showing for the first time that adjuvants can
dramatically impact the IgG subclass profile in macaques. The DIP-10 PALFQ regimen
also increased vaginal and rectal IgA antibodies to a greater extent. Within lymph
nodes, we observed augmented GC B cell responses and the promotion of Th1 gene
expression profiles in GC Tfh cells. The frequency of GC Tfh cells correlated with both
the magnitude and avidity of anti-Env serum IgG. Together, these data suggest that
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adjuvant-induced stimulation of Th1-Tfh cells is an effective strategy for enhancing
the magnitude and quality of anti-Env antibody responses.
IMPORTANCE The results of the RV144 trial demonstrated that vaccination could
prevent HIV transmission in humans and that longevity of anti-Env antibodies may
be key to this protection. Efforts to improve upon the prime-boost vaccine regimen
used in RV144 have indicated that booster immunizations can increase serum anti-Env
antibody titers but only transiently. Poor antibody durability hampers efforts to develop
an effective HIV-1 vaccine. This study was designed to identify the specific elements in-
volved in the immunological mechanism necessary to produce robust HIV-1-specific an-
tibodies in rhesus macaques. By clearly defining immune-mediated pathways that im-
prove the magnitude and functionality of the anti-HIV-1 antibody response, we will have
the foundation necessary for the rational development of an HIV-1 vaccine.
KEYWORDS antibody, CD4, Tfh, vaccine, adjuvant
CD4 T follicular helper cells (Tfh) are a specialized subset of CD4 T cells that migrateto germinal centers (GCs) within secondary lymphoid organs and provide growth
and differentiation signals to GC B cells within a few days of immunization (1–3). GCs
are populated by antigen (Ag)-activated, rapidly proliferating B cell clones, which rely
on cytokines and costimulatory signals from Tfh cells to undergo immunoglobulin
affinity maturation, class switch recombination, and differentiation to memory B cells
and plasma cells (4–6). The maturation of GC B cells to plasma cells and the resulting
long-lived humoral immunity hinge on effective Tfh help.
Tfh cells are heterogeneous and, depending on inflammatory signals during T cell
priming, differentiate into Th1-, Th2-, and Th17-type Tfh cells (7, 8). Th polarization of a
Tfh cell influences the cytokine profile and costimulatory molecule expression, and
several recent studies demonstrate that within a single vaccine modality, the relative
proportion of Tfh1, -2, or -17 subsets induced following antigen stimulation can
influence the duration and functional quality of the antibody response (9). In the setting
of influenza and human immunodeficiency virus type 1 (HIV-1) vaccination, the fre-
quencies of vaccine-induced Th1-polarized, CXCR3-expressing Tfh cells correlate with
improved antibody titers and enhanced antibody function following immunization
(10–12). These data led us to postulate that by stimulating the production of Th1-Tfh
cells via a tailored vaccine platform, humoral immunity against HIV-1 can be optimized
in both duration and quality.
The RV144 trial found that waning serum anti-HIV-1 envelope (Env) IgG titers
following vaccination corresponded to a decrease in vaccine efficacy (13, 14). Therefore,
there is a critical need to identify strategies that will augment vaccine-mediated
humoral immunity for a successful HIV-1 vaccine. In RV144, the development of
antigen-specific CD4 T cells expressing interleukin-4 (IL-4) and CD40L, both of which are
important for effective Tfh help for B cells (15, 16), positively correlated with anti-HIV-1
Env antibody titers. Furthermore, an increase in the production of HIV-specific CD4 T
cells expressing IL-21, a Tfh cytokine that regulates plasma cell differentiation, was also
observed (17–19). These data underscore the importance of CD4 Tfh cells in HIV-1
vaccine-induced antibody responses and suggest that identifying and targeting the
optimal Tfh subset may be an effective strategy to improve the magnitude and
longevity of anti-HIV-1 Env-specific antibodies.
Based on evidence that Th1-polarized Tfh cells correlate with higher antibody
responses, we set out to investigate empirically whether an HIV-1 vaccine platform
designed to increase the number of Th1-polarized Tfh cells would enhance the func-
tional quality and magnitude of HIV-1 anti-Env antibodies.
Utilizing a novel interferon-induced protein 10 (IP-10)-adjuvanted HIV-1 DNA prime
followed by a monophosphoryl lipid A and QS-21 (MPLAQS-21)-adjuvanted Env
protein boost (DIP-10 PALFQ) in macaques, we show increased HIV-1 anti-Env-specific
binding antibody in serum and mucosal compartments compared to vaccination with
DNA lacking IP-10 and an MPLA-plus-alum-adjuvanted Env protein boost (DPALFA). The
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DIP-10 PALFQ vaccine regimen augmented GC B cell responses and promoted Th1 gene
expression profiles in GC Tfh cells. The number of GC Tfh cells positively correlated with
both the magnitude and avidity of anti-Env-specific antibody responses. We report for
the first time that adjuvants dramatically impact the IgG antibody subclass profile in
rhesus macaques. We made the striking observation that while both vaccine regimens
induced IgG1 antibodies to gp120, the DPALFA regimen generated much greater IgG4
responses. Together, these data show that by stimulating the production of Th1-Tfh cells
during the prime and boost using an adjuvanted vaccine, we can enhance the
magnitude and function of the anti-HIV-1 Env antibody response.
RESULTS
Vaccination regimen. Twenty female rhesus macaques were assigned to one of
two experimental groups. For group 1 (n 10), the DIP-10 PALFQ vaccine group, the Th1
chemokine IP-10, a ligand for and an inducer of CXCR3, was used as a molecular
adjuvant to a DNA vaccine (DIP-10) to prime Th1-type Tfh cells. Group 2 (n 10) animals
received the same DNA vaccine without the adjuvant (Fig. 1). The DNA plasmid
expressed simian immunodeficiency virus SIVmac239 Gag, protease, reverse transcrip-
tase, Tat, and Rev and HIV C.1086 Env, and the DIP-10 plasmid additionally expressed
rhesus IP-10. The DNA was delivered intradermally (i.d.) with electroporation (EP) in
both experimental groups.
Prior to immunizing animals, we evaluated plasmid constructs using 293T cells.
Forty-eight hours following transfection, cells were harvested, and the expression of
HIV proteins was assessed by flow cytometry using the monoclonal antibodies PG9,
PG16, and PGT121 for surface Env; 2F12 for intracellular SIV Gag; and J034D6 for
intracellular IP-10. As illustrated in the flow plots in Fig. 1A, both constructs expressed
comparable levels of Env and Gag proteins as determined by staining with PGT121 and
2F12, respectively. Cellular and secreted IP-10 as determined by intracellular cytokine
staining (ICS) (Fig. 1A) and enzyme-linked immunosorbent assays (ELISAs) (Fig. 1C),
respectively, was specific to the DNAIP-10 construct. When expressed as a percentage of
Gag-positive (Gag) cells, the expression of trimeric Env as determined by binding of
the monoclonal broadly neutralizing antibodies PG9 and PG16, which bind the V1V2
loop, and the V3-binding monoclonal antibody PGT121 showed comparable expression
levels across the two vaccine constructs.
Following DNA immunization, we used clade C C.ZA 1197MB gp140 protein adju-
vanted with Army liposome formulation (ALF) liposomes containing monophosphoryl
lipid A (MPLA) and a detoxified saponin derivative, QS-21 (ALFQ) (20), to boost
Th1-primed responses (DIP-10 PALFQ) (Fig. 1D). Group 2 animals received an unadju-
vanted i.d., EP-delivered DNA prime and protein adjuvanted with an aluminum-
adsorbed ALF formulation (ALFA) (21), wherein the protein was adsorbed to aluminum
hydroxide (AH) and then added to ALF (DPALFA). Blood was collected at weeks 8 and
0 of vaccination and at weeks 1, 2, 4, 8, 18, and 20 following each vaccination, as
indicated. Fine-needle aspirates of lymph nodes (LNs) or LN biopsy specimens (drain-
ing) were collected to examine GC responses, and rectal and vaginal secretions were
sampled to assess mucosal antibodies.
To confirm that the DIP-10 PALFQ vaccine regimen induced relatively higher Th1-
biased inflammatory responses, we evaluated the induction of CXCR3 ligands in serum
using a flow-based Legendplex assay at days 0, 3, and 7 after the 1st protein boost. The
data showed higher relative inductions of IP-10 and interferon-inducible T cell alpha
chemoattractant (I-TAC) in the ALFQ-adjuvanted animals (P  0.01) (Fig. 1E). Monokine
induced by gamma, another CXCR3 ligand, was not induced following the 1st protein
boost in either vaccine regimen (data not shown). We also observed a significant
induction of IL-6 following the ALFQ protein boost. The induction of the chemokine
regulated upon activation, normal T cell expressed, and secreted (RANTES) in both
vaccine groups indicated the presence of activated CD4 and CD8 T cells following
vaccination. In all, these data showed a higher relative magnitude of Th1 chemokines
in the DIP-10 PALFQ vaccine regimen.
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The DIP-10 PALFQ vaccine induces robust and durable anti-Env antibody with
cross-clade breadth. To ascertain whether the induction of greater-magnitude Th1
inflammatory responses elicited anti-Env antibody responses of different magnitudes
between the vaccine regimens, we first evaluated responses against C.1086 gp140 Env
using a binding antibody multiplex assay (BAMA) (22). We have previously shown that
the transient extrafollicular plasmablast response contributes to peak serum IgG anti-
body titers following the boost, while titers at week 8 and beyond are mainly plasma
cell derived (12). Therefore, we assessed antibody levels at weeks 0, 2, and 8 following
each of the protein boosts to capture both extrafollicular (week 2) and plasma cell-
derived (week 8 and beyond) titers. The data showed robust induction of anti-C.1086
Env responses following the 1st protein immunization in all 20 animals and potent
FIG 1 Immunization schedule for the subtype C HIV-1 envelope DNA (D) prime and protein boost (P) vaccine regimen. (A) Flow cytometric
plots illustrating the expression of HIV Env, SIV Gag, and IP-10 by 293T cells transfected with DNA and DNAIP-10 plasmids. (B) Surface
expression of HIV Env based on detection with a panel of monoclonal antibodies, as indicated. (C) IP-10 concentrations in supernatants
of transfected 293T cells show the accumulation of IP-10 following transfection with DNAIP-10. (D) Immunization schedule. Two groups of
10 rhesus macaques each were immunized three times with DNA followed by two immunizations with protein. DNA was delivered
intradermally, and 3 s later, electrical pulses were delivered around the injection site using the Ichor TriGrid array. Group 1 animals (n 10)
received the DNA plasmid expressing IP-10 and an ALFQ-adjuvanted C.ZA gp140 boost (DIP-10 PALFQ). Group 2 (n 10) animals were
immunized with DNA and boosted with ALFA-adjuvanted C.ZA gp140 protein (DPALFA). SQ, subcutaneous. (E) Induction of IP-10, I-TAC,
IL-6, and RANTES in serum after the 1st protein immunization in both vaccine regimens. Significance was tested by a Mann-Whitney test
(*, P 0.05; **, P 0.01; ns, not significant).
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recall of memory B cells following the 2nd protein immunization as evidenced by a
robust boost in antibody responses (Fig. 2A). Strikingly, Env ALFQ-boosted animals
developed significantly higher responses against C.1086 gp140; the median area under
the concentration-time curve (AUC) values in the ALFA and ALFQ vaccine groups were
7,496 and 20,301 at week 0 (P 0.01), 46,481 and 63,469 at week 2 (P 0.001), and
20,714 and 36,709 at week 8 (P 0.0001) after the 2nd protein boost, respectively.
We confirmed these findings by using an independent ELISA to explore C.1086
gp140 anti-Env antibody kinetics after the 2nd protein boost (Fig. 2B). The assay
revealed that anti-Env titers exhibited a median 5-fold increase at week 2 after the 2nd
protein immunization relative to week 0, indicating a successful booster response. In
affirmation of the BAMA data, antibody titers were significantly higher in the DIP-10
PALFQ group than in the DPALFA group at all time points after the 2nd protein boost.
We next assessed the breadth of the serum IgG antibody response and found that
AUC values against CH505 subtype C Env were also significantly higher in the DIP-10
PALFQ group than in the DPALFA group (P 0.01) (Fig. 2C). Similarly, increased responses
against the Con S (group M consensus) and Con C gp140 proteins at week 2 following
the 2nd protein boost in the DIP-10 PALFQ group were sustained at week 8, demonstrat-
ing a greater induction of antibodies with cross-clade breadth using the DIP-10 PALFQ
vaccine regimen (P  0.05) (Fig. 2D and E). We also assessed binding to gp120 V1V2
loops from isolate Case A2, scaffolded on murine leukemia virus (MLV) gp70, at weeks
2 and 8 and found that a significantly higher specificity for these important regions was
induced by the DIP-10 PALFQ vaccine regimen following the second protein boost
(P 0.05) (Fig. 2F).
Based on the significantly elevated anti-Env antibody responses in the DIP-10 PALFQ
vaccine regimen, we sought to quantify the decline in antibody magnitude. To this end,
we calculated fold changes in titers at weeks 8 and 18 following the 2nd protein boost
relative to titers at week 8 after the 1st protein boost. The significantly higher titers at
week 8 (mean of 1.7-fold in the DPALFA group versus 4.5-fold in the DIP-10 PALFQ group;
P 0.05) and week 18 (mean of 0.3-fold in the DPALFA group versus 1.3-fold in the DIP-10
PALFQ group; P  0.01) after the 2nd protein boost in DIP-10 PALFQ-vaccinated animals
suggested that the DIP-10 PALFQ vaccine regimen was effective at enhancing the
magnitude of anti-HIV-1 Env serum IgG titers (Fig. 2G). Together, these data show that
the DIP-10 PALFQ group had higher induction of cross-clade breadth and elicited strong
binding to a gp70-V1V2 protein and enhanced antibody responses relative to the
DPALFA group.
The DIP-10 PALFQ vaccine elicits high-avidity anti-Env antibody with ADCC and
ADP activities. Next, we quantified the avidity of IgG binding antibodies (as a disas-
sociation constant [Kd]) in sera collected 2 weeks after the final DNA prime and after
each of the protein boosts using surface plasmon resonance (SPR) for C.1086 gp140
protein (23). The data showed that gp140-specific antibodies reached higher avidity
with each sequential immunization in both vaccine groups (P 0.0001) (Fig. 3A and B).
Consistent with the ELISA results (Fig. 2), SPR-based IgG measurements, expressed as
relative units (RU), showed significantly higher gp140 IgG levels in the DIP-10 PALFQ
vaccine group (P  0.0001) (Fig. 3C). Therefore, we normalized avidity measurements
to gp140 binding measurements and observed increased avidities in the DIP-10 PALFQ
vaccine group relative to the DPALFA group, which was suggestive of a more productive
GC reaction in the DIP-10 PALFQ vaccine group (P  0.0001) (Fig. 3C). To confirm that
higher-avidity antibodies in the DIP-10 PALFQ vaccine group were sustained, we deter-
mined avidity 8 weeks following the 2nd protein boost using a 2 M sodium thiocyanate
displacement ELISA with C.1086C gp140 antigen (12). The data showed sustained
induction of higher-avidity antibodies in the DIP-10 PALFQ group (P  0.05) (Fig. 3D),
which was further corroborated by a 0.1 M sodium citrate ELISA (P  0.01) (Fig. 3E).
Notably, higher-avidity antibodies against Con C and Con S gp140 proteins were also
induced by the DIP-10 PALFQ vaccine regimen (P  0.01) (Fig. 3F and G).
After establishing the induction of higher-avidity antibodies in the DIP-10 PALFQ
vaccine group, we next evaluated the capacity of immune sera to neutralize HIV-1 using
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FIG 2 The DIP-10 PALFQ vaccine induces robust anti-Env serum IgG antibody with cross-clade breadth. (A) Kinetics of the C.1086
anti-gp140 IgG response measured by a BAMA in serum at weeks 0, 2, and 8 following each protein boost. The right panel shows
(Continued on next page)
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the classic TZM-bl assay (12). We detected robust activity against MW965.26, a subtype
C tier 1A variant (Fig. 3H), whereas neutralization of tier 1B and tier 2 isolates was
sporadic (data not shown) (24). The data showed higher induction of tier 1A neutral-
izing antibodies in the DIP-10 PALFQ vaccine group (50% infective dose [ID50] ranges at
week 2 after the 2nd protein boost of 37 to 1,126 for the DPALFA group and 195 to 4,977
for the DIP-10 PALFQ group; P 0.01). These titers dropped to an ID50 value of 20 in the
DPALFA group but were maintained at values of between 24 and 1,057 in the DIP-10
PALFQ group (P  0.001). To assess the generation of Fc-mediated antibody effector
responses, we measured antibody-dependent cellular cytotoxicity (ADCC) and
antibody-dependent phagocytosis (ADP) triggered by the engagement of the Fc
receptors on antibody-bound target cells by innate cells (25–27). ADCC was assessed by
measuring the killing of simian-human immunodeficiency virus clade C CH505
(SHIV.C.CH505)-infected CEM.NKR target cells by a rhesus CD16 (FcR3) NK cell line in
the presence of immune serum. As shown in Fig. 3I, serum from DIP-10 PALFQ-vaccinated
animals demonstrated significantly greater ADCC activity at week 2 and week 8 after
the 2nd protein boost than did serum from DPALFA-immunized animals (P  0.01).
Serum collected from DIP-10 PALFQ-vaccinated animals at week 8 after protein boost 2
also demonstrated significantly greater phagocytosis of C.1086 gp120-coated beads by
the CD32 (FcR2) and CD64 (FcR1) THP-1 monocytic cell line (Fig. 3J and K). To
determine if the adjuvants given to animals in the vaccine groups generated different
rhesus IgG subclass antibody repertoires, we quantified C.1086 gp120-specific IgG1,
IgG2, IgG3, and IgG4 by an ELISA. We found that the levels of IgG2 and IgG3 antibodies
were extremely low and did not differ between groups (Fig. 3L). However, DIP-10
PALFQ-vaccinated animals had higher levels of gp120-specific IgG1 (P 0.0001) (Fig. 3L),
while DPALFA-vaccinated animals had higher levels of gp120-specific IgG4, resulting in
a markedly elevated IgG1/IgG4 ratio in the DIP-10 PALFQ vaccine group (P  0.001) (Fig.
3M). The IgG4 detection antibody (clone 78A) showed minimal cross-reactivity to IgG1
and IgG3 subclass antibodies, indicating the specificity of the antibody for rhesus IgG4
(data not shown). These results are consistent with reports that antibodies of the IgG1
subclass are the most abundant in rhesus macaques (28, 29).
The DIP-10 PALFQ vaccine elicits robust anti-Env antibody in vaginal and rectal
mucosal compartments. Having established the induction of higher serum IgG anti-
body titers in DIP-10 PALFQ-vaccinated animals, we next sought to determine whether
mucosal anti-Env antibodies were also correspondingly increased. To this end, we
assayed rectal and vaginal secretions for C.1086 gp140-specific IgG and IgA antibodies
at baseline and longitudinally after each of the protein boosts. We next asked whether
either vaccine regimen induced mucosal antibody responses; we focused on quantify-
ing concentrations following the 1st protein boost, a time point when mucosal IgG and
IgA concentrations are above baseline (background) levels in the majority of the
animals. The appearance of gp140-specific IgG in secretions closely mimicked the kinetics
of the serum IgG antibody response, with each protein boost increasing the levels of
Env-specific IgG antibodies in vaginal and rectal secretions (Fig. 4A and B). As in serum,
the DIP-10 PALFQ vaccine regimen generated higher levels of specific IgG in secretions
than did the DPALFA vaccine. The gp140-specific IgA in vaginal and rectal secretions was
also increased to a greater extent by the DIP-10 PALFQ vaccine regimen (Fig. 4C and D).
Notably, at week 16 after the 2nd protein boost, vaginal IgA antibodies were still above
the limit of detection in most DIP-10 PALFQ-vaccinated animals but in only 2 of 10
DPALFA-vaccinated animals. Analysis of gp140-specific IgA in serum revealed higher
FIG 2 Legend (Continued)
scatter plot values for each animal at weeks 0, 2, and 8 after the 2nd protein boost. (B) Kinetics of the C.1086 gp140-specific anti-Env
IgG response measured by an ELISA after the 2nd protein boost. The right panel shows titers for each individual animal. (C to F) A
BAMA was used to measure responses against CH505 gp140 (C), Con C gp140 (D), Con S gp140 (E), and gp70-V1V2 Case A2 (F). (G)
Fold changes in antibody titers at the indicated time points after the 2nd protein boost relative to the 1st. Kinetic data show
geometric means. Vertical dotted lines show immunization time points. In dot plots, geometric means are indicated as horizontal
lines. Statistical significance across vaccine regimens was tested using the Mann-Whitney U test (*, P 0.05; **, P 0.01; ***,
P 0.001; ****, P 0.0001).
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FIG 3 The DIP-10 PALFQ vaccine elicits high-avidity anti-Env antibody with ADCC and ADP activities. (A) Surface plasmon
resonance (SPR) was used to determine the avidity index (AI) in serum 2 weeks after the third DNA immunization and each
protein boost using C.1086 gp140 protein immobilized onto sensor chips. Violin plots show medians (bold lines) and
interquartile ranges (dashed lines) in both vaccine groups, with each sample run in quadruplicate. Lower values indicate higher
avidities. (B) SPR-based AI values for the two vaccine regimens over time. (C) Significantly higher IgG values for DIP-10 PALFQ
2 weeks after the 2nd protein boost (expressed as relative units, as measured by SPR) and higher avidity after normalizing
avidity to gp140 IgG RU. Lower values indicate higher avidities. (D and E) AI measured against C.1086 gp140 using 2 M sodium
thiocyanate (D) and 0.1 M sodium citrate (E) at week 8 after the 2nd protein boost. (F and G) AIs against Con C (F) and Con
S (G) gp140 measured using 0.1 M sodium citrate at week 8 after the 2nd protein boost. (H) Serum neutralizing antibodies
(NAb) were assessed against tier 1A (MW965.26) pseudovirus, and the 50% infective dose (ID50) was determined. (I) ADCC
(Continued on next page)
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induction in the DIP-10 PALFQ group (Fig. 4E). However, the kinetics of the serum IgA
response in DIP-10 PALFQ- as well as DPALFA-vaccinated animals differed strikingly from
the mucosal IgA responses, especially in the reproductive tract (Fig. 4C and D),
suggesting that a true mucosal (locally derived) IgA response was generated in these
animals. This was most evident after the 2nd protein boost, when vaginal IgA antibod-
ies to gp140 were found to be dramatically increased but serum IgA antibodies were
reduced (Fig. 4A and C). Together, these data demonstrate that the DIP-10 PALFQ vaccine
regimen was more effective than the DPALFA regimen for generating higher-magnitude
Env binding antibodies in serum and secretions as well as serum IgG antibodies with
greater breadth, avidity, and function.
Next, we determined whether the relatively higher concentrations of anti-gp140
antibody in mucosal secretions in the DIP-10 PALFQ vaccine group might result in delayed
acquisition against the clade C transmitted/founder (T/F) virus SHIV.C.CH505. To this
end, we challenged monkeys intravaginally with eight repeat, low-dose inoculations of
SHIV.C.CH505 at week 20 after the 2nd protein boost. While we observed no significant
differences in the delay in acquisition between the vaccine groups, 3 of 10 animals in
the DIP-10 PALFQ vaccine group were protected, relative to 0 of 10 animals in the DPALFA
group (Fig. 4F). We observed that the mucosal gp140 IgG antibody concentration at
week 16 after the 2nd protein boost was a correlate of protection, with higher
concentrations correlating with delayed acquisition in infected animals in each of the
vaccine groups (r 0.94 and P 0.01 for the DIP-10 PALFQ vaccine group [n 10];
r 0.78 and P 0.01 for the DPALFA vaccine group [n 10]) (Fig. 4G).
The DIP-10 PALFQ vaccine induces Env-specific Tfh cells and GC Tfh cells with
distinctive Th1 signatures. The DIP-10 PALFQ vaccine promoted anti-Env antibody
magnitude and functionality following the 1st protein boost. Based on this finding, we
wanted to determine whether this vaccine regimen also correspondingly enhanced Tfh
cells in the periphery and LNs. To this end, we first assessed whether higher frequencies
of Env-specific Tfh cells were induced in blood 7 days after the 1st protein boost,
corresponding to the peak of the effector response. Peripheral blood mononuclear cells
(PBMCs) were stimulated with overlapping peptide pools representing Con C gp140
together with HIV-1 C.1086 Env gp140 protein. The induction of the activation markers
CD25 and OX40 was assessed by flow cytometry after stimulation (Fig. 5A, flow plot)
(30). The analysis revealed a higher frequency of Env-specific CD4 T cells in the
circulation of DIP-10 PALFQ animals. When expressed as a percentage of CD95 CD4 T
cells, median frequencies of Env-specific CD4 T cells were on average 10-fold higher in
the DIP-10 PALFQ group, indicative of a higher-magnitude Env-specific Tfh response
(P 0.001) (Fig. 5B). In all, these data showed robust recall responses following the 1st
protein boost, with a higher relative magnitude of Env-specific Tfh cells in the DIP-10
PALFQ vaccine regimen.
Next, we assessed LN responses using biopsy specimens collected on day 14 after
the 1st protein boost and identified GC Tfh cells as CXCR5 PD-1 cells (Fig. 6A, red
population) and GC B cells as Ki-67 Bcl-6 CD20 cells. As expected, GC Tfh cells
expressed Bcl-6 and ICOS, and consistent with the functional ability of Tfh cells (12), our
ex vivo analysis of sorted GC Tfh cells revealed their capacity to support IgG production
by autologous LN B cells (Fig. 6B). Evaluation of GC Tfh frequencies over the course of
immunization revealed a significant induction of GC Tfh cells 2 weeks after protein
boost 1 relative to baseline and significantly higher frequencies 2 weeks after protein
boost 2 than at week 0 of protein boost 2 (Fig. 6C).
FIG 3 Legend (Continued)
activity against SHIV CH505-infected target cells. Data are presented with week 0 serum ADCC values normalized to 0%
(dashed gray line). (J) ADP using clade C Du151 gp120-coated beads was measured using sera from week 8 after the 2nd
protein boost at serum dilutions ranging from 1:100 to 1:2,500. (K) Individual ADP scores at a 1:500 serum dilution. (L) C.1086
gp120-specific IgG subclass analysis was performed by an ELISA using serum collected 8 weeks after the 2nd protein boost.
(M) IgG1/IgG4 ratios across vaccine groups at week 8 after the 2nd protein boost. Statistical significance across vaccine
regimens was examined using the Mann-Whitney U test, and within-group differences over time were tested using a Wilcoxon
matched-pairs signed-rank test (*, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001).
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FIG 4 The DIP-10 PALFQ vaccine elicits robust anti-Env antibody in vaginal and rectal mucosal secretions. Concentrations of anti-C.1086 gp140
IgG and IgA in secretions were measured by a BAMA and adjusted in accordance with the total IgG and IgA, respectively, to obtain the
specific activity. (A to D) Development of gp140-specific IgG (A and B) and IgA (C and D) in vaginal and rectal secretions. (E) Kinetics of
the C.1086 gp140-specific IgA response in serum. Horizontal dashed lines represent the cutoff for significance. Kinetic data show geometric
means. Vertical dotted lines show immunization time points. In dot plots, data from after the 2nd protein boost are shown, and geometric
means are indicated as horizontal lines. (F) Kaplan-Meier plot showing acquisition rates following eight repeat intravaginal challenges with
SHIV.C.CH505. (G) Vaginal anti-gp140 IgG concentrations at week 16 after the 2nd protein boost correlated with a delay in acquisition in
infected animals in both vaccine regimens (DIP-10 PALFQ vaccine regimen, n 7; DPALFA vaccine regimen, n 10). Statistical significance was
tested using an unpaired, two-tailed Mann-Whitney U test (*, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001), and correlations with
a Spearman rank correlation.
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While the frequencies of GC Tfh cells were not significantly different between
experimental groups, we found that GC B cell frequencies were significantly higher in
the DIP-10 PALFQ vaccine regimen (n 10 animals in each group following the 1st
protein boost; a median for the DPALFA group of 14.2% [of CD20 cells] versus a median
for the DIP-10 PALFQ group of 25% [P 0.05]), and the frequency of GC Tfh cells strongly
correlated with GC B cell responses (Fig. 6D). Importantly, Env-specific Tfh cell frequen-
cies in the LNs directly correlated with GC Tfh cell frequencies but not memory Tfh cells,
indicating that GC Tfh cells were enriched for vaccine-induced follicular cells
(P 0.0001) (Fig. 6D). Next, we assessed the expression of CXCR3, which is heteroge-
neously expressed by GC Tfh cells (Fig. 6E), and found higher expression levels of CXCR3
on GC Tfh cells in the DIP-10 PALFQ group. We observed that the frequency of CXCR3
Tfh cells within the GC was directly associated with gp140 serum antibody titers at week
18 after the 2nd protein boost (r  0.44; P 0.05) (Fig. 6E). Examination of GC B cells
showed elevated CXCR3 expression in GC B cells from the DIP-10 PALFQ vaccine group
(P 0.05) (Fig. 6F). Notably, T-bet expression on B cells, a marker of memory B cells (31),
corresponded with CXCR3 expression, suggesting a mechanistic basis for enhanced
antibody responses in the DIP-10 PALFQ vaccine group. Together, these data support the
contention that Th1 skewing of CD4 Tfh cells may support higher anti-Env antibody
levels.
To gain insights into the molecular mechanisms underlying successful antibody
responses, we next determined the transcriptional signature in GC Tfh cells. To achieve
this goal, we sorted naive CD4 cells, CD4 Tfh cells, and memory CD4 cells from the LNs
of 3 DIP-10 PALFQ group animals with the highest gp140 serum IgG levels at week 8 after
the 1st protein boost. These subsets were identified using the following markers: CD4
CD95 for naive cells, CD95 CXCR5 PD-1/ for Tfh cells, CD95 CXCR5 PD-1 for
memory Tfh cells, and CD95 CXCR5 PD-1 for memory non-Tfh cells.
RNA samples meeting quality control checks were sequenced using a 3=-tag RNA-
sequencing (RNA-Seq) library prep protocol at the UC Davis Genome Center using the
Illumina HiSeq 4000 platform. Prior to the analysis of sequenced single-end reads,
genes with fewer than 40 counts per million reads were filtered, leaving 7,086 genes.
Differential expression analyses were conducted using the limma-voom Bioconductor
pipeline (32) to compare the transcriptome profiles of antigen-experienced CD4 sub-
sets to those of naive cells. Principal-component analysis of the 500 most variable
FIG 5 The DIP-10 PALFQ vaccine induces Env-specific T cells and Tfh cells in blood. (A) Gating strategy to
identify CXCR5 OX40 CD25 Env-specific Tfh cells within PBMCs after stimulation with both whole
C.1086 gp140 protein and pooled overlapping peptides representing Con C gp140. The flow plot
illustrates responses following stimulation with Env or volume-controlled DMSO (NS). SSC, side scatter;
FSC, forward scatter. (B) Frequency of Env-specific CD4 T cells at week 1 after the 1st protein boost.
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FIG 6 The DIP-10 PALFQ vaccine induces GC Tfh cells with distinctive Th1 signatures. (A) Gating strategy to identify GC Tfh cells and GC B cells in LNs
2 weeks after the 1st protein boost. Histograms show higher relative expression levels of Bcl-6 and ICOS in GC Tfh cells than in naive CD4 T cells.
Expression in GC B cells is also shown. (B) Total IgG was measured in ex vivo coculture experiments with sorted GC Tfh cells and autologous LN
(Continued on next page)
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genes based on coefficients of variation showed that CD4 transcriptomes clustered by
cellular differentiation status, with memory CD4 T cells (both CXCR5 and CXCR5)
sharing transcriptional signatures relative to naive and Tfh subsets (data not shown). To
extract information on biologically relevant gene sets, we performed gene set enrich-
ment analysis (GSEA) with the goal of determining biological pathways that were
enriched in Tfh cells in the Th1 vaccine regimen. Genes regulating interleukin-12 (IL-12),
tumor necrosis factor alpha (TNF-), interferon gamma (IFN-), and IL-6 production
were strongly enriched in Tfh cells. Consistent with the metabolic activity of effector
cells and the functional capacity of Tfh cells, pathways regulating cellular metabolism,
glucose homeostasis, and B cell proliferation were also enriched.
To determine the transcriptional activity of Tfh cells in the DIP-10 PALFQ vaccine group,
we focused on differentially induced genes in Tfh cells relative to naive cells (n 89;
adjusted P value of 0.05) (Fig. 6G), of which the induction of key Tfh transcripts,
including CXCR5, ICOS, and Bcl-6, was common to both Tfh cells and memory Tfh cells.
A heat map shows the expression of genes differentially expressed in Tfh cells relative
to naive cells across four sorted CD4 subsets. Consistent with the representation of
DIP-10 PALFQ genes in the GSEA, Tfh cells showed higher expression levels of TBX21 and
IFN- (Fig. 6G and H). The class IV semaphorin protein (SEMA4A), a costimulatory
molecule expressed by DIP-10 PALFQ cells (33), was significantly induced, as was high-
mobility-group box 1 (HMGB1), an inflammatory mediator regulating TNF and IL-6
production (34). The induction of IL-18 receptor (IL-18R) suggested the capacity of IL-18
to drive IFN- production within the GC (35). Likewise, we noted higher expression
levels of receptor-interacting serine/threonine kinase 2 (RIPK2), which drives IFN- in
Th1 cells and contributes to Th1 differentiation (36). The corresponding downregulation
of IL-4R in Tfh cells indicated an enrichment of the Th1 program within Tfh cells in DIP-10
PALFQ-vaccinated animals. This, together with the increased protein expression of
CXCR3 within the GC, suggested that CD4 T cell help for humoral immunity was driven
by Th1-Tfh cells in the DIP-10 PALFQ vaccine regimen.
DIP-10 immunization induces systemic expansion of proinflammatory mono-
cytes and enhances GC Tfh responses. Based on the increased frequencies of Env-
specific Tfh cells and evidence for the induction of a Th1 transcriptome program in DIP-10
PALFQ-vaccinated animals after the 1st protein boost, we sought to assess Tfh responses
during the DNA priming phase. First, we evaluated blood to quantify activated CXCR5
CD4 T cells in both vaccine groups (Fig. 7A). Based on the coexpression of ICOS and
PD-1, activation markers induced upon T cell receptor (TCR) stimulation, the data
showed that DNA immunization significantly increased the relative frequencies and
absolute counts of ICOS PD-1 CXCR5 CD4 T cells in blood at day 14 (median
frequencies of 3.38% at day 0 and 6.7% at day 14 [P 0.0001] [n 20]; absolute counts
of 3.04 at day 0 and 8.7 at day 14 [P 0.01] [n 20]) (Fig. 7A) in both experimental
groups, indicating that DNA delivery by electroporation was immunogenic.
Next, we assessed whether DNA immunization elicited humoral responses against
SIV Gag and HIV Env proteins expressed in the plasmid. We found that detectable
FIG 6 Legend (Continued)
B cells to demonstrate the B helper capacity of the Tfh cells. (C) Frequencies of GC Tfh cells in LNs at specified time points. Symbols indicate
significant differences from the baseline for protein 1 and from day 0 for protein 2. (D) Dot plot illustrating higher frequencies of GC B cells in the
Th1 vaccine group and correlations between frequencies of GC Tfh cells and GC B cells or Env-specific Tfh cells in LNs. Frequencies of Env-specific
CD4 T cells in LNs (right) correlate with GC Tfh cells. (E, left) Histogram illustrating relative CXCR3 expression in GC Tfh cells and GC B cells. (Right)
Dot plots showing significantly higher CXCR3 expression levels on GC Tfh cells in the Th1 vaccine group. Serum antibody titers at week 18 after
the 2nd protein boost correlate with the frequency of GC Tfh cells and the proportion of CXCR3-expressing GC Tfh cells 2 weeks after the 1st protein
boost. (F, left) Dot plot showing significantly higher CXCR3 expression levels on GC B cells from animals in the Th1 vaccine group. (Right) Flow plots
illustrating higher expression levels of CXCR3 on T-bet memory B cells. (G) Log fold change values for key Tfh and Th1 genes in Tfh and memory
(mem) Tfh cells in lymph nodes of Th1-vaccinated animals (adjusted P value of 0.05). (H) Heat map showing the expression of genes differentially
expressed in Tfh cells relative to naive cells across four sorted CD4 subsets. Blue and red represent high and low relative log2 gene expression values,
respectively. For the construction of heat maps, log2 gene expression values (counts per million) for the most differentially expressed genes in the
comparison of Tfh versus naive cells were selected by the threshold of an adjusted P value of 0.05. Statistical significance was tested using an
unpaired, two-tailed Mann-Whitney U test. Spearman coefficient-of-correlation values were computed to determine associations (*, P 0.05; ****,
P 0.0001).
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FIG 7 DNAIP-10 immunization induces systemic expansion of proinflammatory monocytes and enhances GC Tfh responses.
(A) Gating strategy to identify activated CXCR5 CD4 T cells in blood on day 0 and day 14 following the 3rd DNA
immunization and transient accumulation of ICOS PD-1 CXCR5 cells in blood of all animals (n 20) when expressed
as relative frequencies (left) or absolute counts (right). (B and C) Kinetics of the SIVmac239 anti-Gag IgG response (B) and
the C.1086 gp140-specific anti-Env IgG response (C) measured by an ELISA after DNA immunization at the indicated time
points. Significance is indicated for all time points relative to baseline titers. (D) Gag-specific CD4 T cell responses measured
at week 1 after DNA3 using AIM- and ICS (IFN- TNF-)-based assays. (E) Gating strategy to identify inflammatory CD14
CD16monocytes in blood. (F) Frequency of CD14 CD16 (% HLA-DR) monocytes following the 3rd DNA immunization.
(G) Comparison of proinflammatory monocytes in blood of DNA- and DNAIP-10-primed animals. (H) Frequencies of GC Tfh
cells in fine-needle aspirates of draining LNs from DNA- and DNAIP-10-primed animals on day 14 after the 3rd DNA
(Continued on next page)
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responses to Gag were observed in 45% of animals at week 2 of the 1st DNA prime, in
65% at week 2 following the 2nd DNA prime, and in all animals following the 3rd DNA
prime (DNA3) (Fig. 7B [significance symbols compare immunization time points relative
to the baseline]). Antibody responses to C.1086 Env were low and undetectable until
the 2nd DNA prime (data not shown) but were observed in the majority of animals
following DNA3 (Fig. 7C [significance symbols compare immunization time points
relative to the baseline]). Gag and Env antibody titers were not significantly different
between the vaccine regimens during the DNA primes. Based on the robust induction
of anti-Gag antibody responses, we determined whether Gag-specific CD4 T cells were
induced at week 1 following DNA3, when the CD4 effector response peaked. PBMCs
were stimulated with pooled SIVmac239 Gag peptide pools and interrogated for the
expression of activation markers (activation-induced marker [AIM] assay) and for the
induction of cytokines (ICS). The AIM assay captured a higher proportion of Gag-specific
CD4 T cells (Fig. 7D), and together, these data indicated that the DNA immunization was
sufficiently immunogenic to prime T and B cell responses.
Based on the induction of antibody and T cell responses following DNA3, we next
assessed whether a concomitant acute induction of proinflammatory monocytes (in-
nate cells that drive Tfh responses) preceded the appearance of these cells in blood (37,
38). We quantified the frequencies of CD14 CD16 HLA-DR CD3 CD20 cells in
blood (Fig. 7E and F) and discovered a rapid and robust expansion of proinflammatory
monocytes in both vaccine groups, with significantly higher induction in the DIP-10
PALFQ vaccine group (Fig. 7G). Based on this, we asked if LN responses differed between
vaccine groups. Strikingly, the GC Tfh cell frequencies within the fine-needle aspirates
of the draining LN were higher in the DIP-10 PALFQ vaccine group following the 3rd DNA
immunization (Fig. 7H). Notably, the greater inflammatory response was associated
with increased levels of serum IgG antibodies, linking the innate immune response to
the priming of effective CD4 Tfh help (Fig. 7I).
DISCUSSION
The present study gives rise to three main conclusions: first that an HIV-1 vaccine
platform designed to promote Th1-polarized Tfh cells increases the number of circulat-
ing Env-specific Tfh cells, enhances GC responses, increases anti-Env binding antibody
titers in sera, and stimulates serum antibody effector functions; second that a Th1
vaccine regimen can elicit anti-Env vaginal and rectal IgA responses; and third that
induction of high-avidity antibodies, reflective of productive GC responses, is engen-
dered by a Th1 vaccine regimen. Collectively, the data suggest that adjuvant-induced
stimulation of Th1-Tfh cell production during the vaccine prime and boost is an effective
strategy to enhance the magnitude and functionality of the anti-Env antibody re-
sponse.
Productive T cell responses critically depend on cytokine signals during priming, and
recent studies demonstrate that monocyte-derived cytokines drive effective CD4 T cell
differentiation and Tfh responses (38–40). Here, investigation of the kinetics of proin-
flammatory monocytes, cellular innate biomarkers of adjuvanticity, revealed a transient
increase in CD14 CD16 monocytes in blood, with a higher relative increase in the
DIP-10 PALFQ vaccine group. Strikingly, fine-needle aspirates of the draining LNs showed
higher GC frequencies in the DIP-10 PALFQ vaccine group, indicating active/productive
GC responses. Notably, the improved inflammatory response was associated with
increased antibody magnitude, linking the innate immune response to the effective
induction of CD4 Tfh cells. Although titers against Gag and Env were not significantly
different between the vaccine regimens during the prime, it is possible that higher
frequencies of memory B cells, which we did not quantify, were induced with the Th1
FIG 7 Legend (Continued)
immunization. (I) Spearman rank correlations between frequencies of proinflammatory monocytes in blood on day 3 and
C.1086C gp140 IgG antibodies in serum on week 8 following the 2nd protein boost. Between-group differences were
assessed using the Mann-Whitney U test (*, P  0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001).
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prime. Indeed, several recent studies show that potent priming of the immune re-
sponse sets the stage for stronger boosting of cellular and humoral immunity in the
settings of DNA prime and NYVAC boost and of adenovirus type 5 (Ad5) prime and
NYVAC boost vaccine regimens (25, 41). The effectiveness of priming is not limited to
CD4 T cells and B cells; a DNA vaccine targeting conserved elements of SIV Gag robustly
primes cytotoxic T cells, which are effectively boosted following a long rest period (42,
43). These data open the possibility of a critical window of opportunity during the
priming phase. This window can be exploited to prime for long-lasting, durable CD4 T
cell, CD8 T cell, and antibody responses to HIV-1 vaccination.
HVTN studies 070 and 080 employed the IL-12 DNA-adjuvanted plasmid with the
subtype B Pennvax-B (PV) DNA plasmid and showed 80% response rates after the third
DNA vaccination in recipients of PV plus IL-12 (PVIL-12), compared to a 44% response
rate with the PV vaccine alone. A subsequent follow-up study demonstrated a robust
recall of binding anti-Env antibody titers with ADCC activity following a modified
vaccinia virus Ankara (MVA) boost in PVIL-12 recipients (44, 45). Because IL-12 is a
classic innate mediator of Th1 responses, the data suggest that an increase in Th1 GC
Tfh cells may underlie the observed effects. Correspondingly, studies in rhesus ma-
caques with an ALVAC prime and ALVACgp120 protein boost using SIV immunogens
showed higher SIV Env titers with MF59 than with aluminum-adjuvanted protein boosts
2 weeks following the final immunization (46). While Tfh responses and memory anti-
body titers were not examined, a recent study in humans showed enhanced binding
antibody titers 26 weeks after booster immunization with a Th1 glucopyranosyl lipid
adjuvant formulated in a stable emulsion (GLA-SE)-adjuvanted malaria antigen relative
to one formulated in aluminum (47). These studies, in conjunction with our report,
provide support for the immune potential of Th1 Tfh cells in fostering high-magnitude
antibody titers. In contrast, a study using a homologous subtype C protein immuniza-
tion reported the induction of higher anti-Env antibody titers with aluminum hydroxide
(Alhydrogel) than with AddaVax, an MF59 analog, in rabbits (48). Collectively, these
data indicate the importance of detailed studies to understand the context in which Th1
responses are superior to mixed Th1 and -2 responses and how viral versus DNA vectors
and subunit proteins influence this paradigm.
Our findings raise the question of the mechanisms underlying the DIP-10 PALFQ
vaccine-mediated enhancement of Tfh responses. A few possibilities can be explored.
IP-10 increases dendritic cell-T cell interactions, which could have favored Tfh differen-
tiation (49). IP-10 also increases IL-6 production in B cells, which is known to support Tfh
differentiation and enhance plasma cell survival (50). This, together with the potent
immunostimulatory potential of the MPLAQS-21 boost, may have synergized to
enhance Tfh responses numerically and favored the Th1 differentiation program within
Tfh cells (51). Indeed, GC Tfh cells induced following viral infections, where Th1 inflam-
matory responses predominate, express Bcl-6, Tbx21, IFN-, and IL-21, consistent with
the induction of Th1-type Tfh cells (52). Transcriptomic analysis of Tfh cells following the
1st protein boost in the DIP-10 PALFQ vaccine regimen shows the coordinate expression
of Th1-regulated genes, as evidenced by the enrichment of pathways related to IFN-
signaling. It should be noted, however, that transcriptional analysis was performed on
only 3 animals within the DIP-10 PALFQ group with the highest-magnitude antibody
responses and therefore may have yielded false-positive targets and furthermore may
not be representative of the GC Tfh signature elicited by the DIP-10 PALFQ vaccine
regimen. Nonetheless, the higher relative expression levels of the Th1 chemokine
receptor CXCR3 in GC Tfh cells and GC B cells and CXCR3 ligands in sera lend support
to the gene expression data. Together, our transcriptomic and phenotypic data on Tfh
cells indicate a role for adjuvant-induced quantitative (increased Tfh numbers) and
qualitative (increased proportion of Th1 Tfh cells) effects on antibody magnitude.
Mechanistic studies are needed to discern the respective contributions of increased Tfh
numbers versus Th1 skewing of Tfh cells to antibody responses, as both of these
characteristics are inextricably linked in the present study. Additionally, because our
vaccine regimen differed by two components, IP-10 in the prime and ALFQ during the
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boost, further studies are needed to determine the specific role of the IP-10 prime
versus the ALFQ boost in driving CD4 Tfh and antibody responses. This will enable us
to address whether the Th1 boost synergized with the Th1 prime to enhance antibody
titers and functionality or if a Th1 prime/Th1 boost alone would be sufficient to elicit the
observed anti-Env antibody profiles.
While the DIP-10 PALFQ vaccine regimen increased the magnitude of anti-Env IgG
titers in the vaginal mucosa, which correlated with decreased acquisition in each of the
vaccine groups, our study was not powered to assess protection from acquisition across
the vaccine regimens. Furthermore, the lack of an unvaccinated control group pre-
cludes the determination of vaccine efficacy and is a major caveat to the interpretation
of acquisition outcomes. Therefore, more extensive larger-scale studies are needed to
assess whether the DIP-10 PALFQ vaccine regimen induced protective antibodies with the
capacity to mediate effective neutralization or antibody effector functions at the
vaginal mucosa. Notably, in contrast to a previous study showing an increased risk of
intrarectal acquisition with MF59 relative to an alum-adjuvanted protein immunization
(46), the DIP-10 PALFQ vaccine regimen did not increase the risk of vaginal acquisition in
the present study. While these studies differ in the routes of mucosal transmission, the
difference in outcomes may also be attributed to the timing of exposure following the
final immunization, i.e., 4 weeks in the previous study versus 20 weeks in the present
study. It is possible that the presence of a higher frequency of CD4 T cell effectors at
the rectal mucosa 4 weeks following immunization increased the acquisition risk, which
could have contributed to the observed differences in outcomes. Indeed, higher
frequencies of CCR5 CD4 T cells in rectal mucosa were observed in vaccinated
monkeys experiencing breakthrough infections than in those remaining uninfected
following a low-dose intrarectal challenge (53). Therefore, whether increased immuno-
genicity detracts from protection is an important safety consideration in the use of Th1
adjuvants and other highly immunogenic vaccine platforms (46). This is particularly
important as the HIV coreceptor CCR5 is primarily expressed on Th1 cells (12). Never-
theless, because Th1 cells also produce CCR5 ligands, it is important to determine the
frequency of Th17 cells at the mucosal portals following immunization, as Th17 cells are
preferential targets of infection within the vaginal mucosa (54). Another consideration
is that the studies were performed on females and did not encompass the possible
variability in vaccine responses between sexes. Therefore, going forward, it is critical to
determine and confirm if a Th1 vaccine regimen will also enhance antibody responses
in males.
In addition to adjuvant-dependent modulation of Tfh responses, our IgG subclass
results also support the conclusion that the DIP-10 PALFQ and DPALFA vaccine regimens
induced qualitatively different GC responses. This is also the first study to show that
adjuvants can dramatically impact the IgG antibody subclass profile in rhesus ma-
caques. We made the striking observation that while both vaccine regimens induced
IgG1 antibodies to gp120, the DPALFA regimen generated much greater IgG4 responses.
The Th2-promoting aluminum adjuvant is most likely responsible for the increased IgG4
in DPALFA animals because both vaccine groups received ALF liposomes. Rhesus IgG4
antibodies can mediate phagocytosis, but overall, they appear to have poor effector
functions (55, 56), and the most functional IgG subclass in macaques has been reported
to be IgG1 (56). Humans immunized with an alum-formulated HIV-1 gp120 protein have
been found to develop IgG1 and IgG4 but not IgG2 and IgG3 antibodies (57). However,
important functional differences in IgG subclass antibodies and FcR biology between
nonhuman primates and humans (58, 59), and the fact that rhesus IgG subclasses are
numbered by serum abundance and not function, preclude direct comparisons be-
tween species. Another consideration is that differing antigen affinities between IgG
subclasses for HIV-1 gp140 could confound quantitation, raising the possibility that
subclass differences may be driven by differential affinities/epitope specificities rather
than differential magnitudes. Therefore, more conclusive studies are needed to evalu-
ate these possibilities.
Another notable observation was the induction, in DIP-10 PALFQ-vaccinated animals,
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of a robust anti-Env vaginal IgA response with an accompanying decline in serum IgA
antibodies after the 2nd protein immunization. This incongruity between vaginal and
serum IgA responses was also observed in the DPALFA vaccine group, suggesting that
ALF liposomes may have generated IgA plasmablasts that homed to the reproductive
tract or possibly Th17-like Tfh cells, which promote IgA responses in mucosal LNs (60,
61). The Th1-biased ALF and ALFQ adjuvants have been reported to generate Th17
responses in mice, with ALFQ being more effective and additionally generating IgA
antibodies (62). Future studies of Tfh cell subsets and IgA plasma cells in mucosal LNs
will be required to determine if our Th1 vaccine regimen may have promoted IgA
responses in the female reproductive tract, and in the rectum to a lesser extent, by
generating Th17 cells.
In summary, our findings demonstrate that Th1-DNA priming substantially increases
the frequency of Env-specific Tfh cells and that Th1-Env protein boosting results in
greater production of anti-Env IgG1 antibodies with enhanced magnitude, breadth,
avidity, and function. How this regimen can be further optimized to significantly
enhance and induce robust tier 2 neutralizing antibodies is an important question that
warrants further study.
MATERIALS AND METHODS
Rhesus macaques. Twenty adult female colony-bred rhesus macaques (Macaca mulatta) were
housed at the California National Primate Research Center and maintained in accordance with American
Association for Accreditation of Laboratory Animal Care guidelines. All studies were approved by the
University of California, Davis, Institutional Animal Care and Use Committee (IACUC). At study initiation,
animals were 3.5 to 4.5 years of age with a median weight of 5.3 kg; were SIV negative (SIV), simian
T-cell leukemia virus negative (STLV), and simian retrovirus negative (SRV); had no history of dietary
or pharmacological manipulation; and had intact ovaries.
Immunizations and challenges. DNA immunizations were administered via intradermal injection
with electroporation utilizing the Ichor TriGrid array (Ichor Medical Systems) at weeks 0, 8, and 16. For
each DNA immunization, two groups of 10 animals received 4 mg of the pGA2/JS2 plasmid DNA vector
(63) encoding either SHIV C.1086 T/F Env plus interferon-induced protein 10 (IP-10) (group 1) or SHIV
C.1086 T/F Env alone (group 2). Details of the SHIV DNA construct were described previously (64). At
weeks 30 and 44, group 1 animals received boosts with 100 g C.ZA 1197MB gp140 protein (Immune
Technology) adjuvanted with 100 g MPLA plus 50 g QS-21 (ALFQ), and group 2 animals received 100
g C.ZA 1197MB gp140 adjuvanted with 100 g MPLA plus 600 g aluminum (ALFA). The protein
formulation (100 g protein in a 500-l formulation) was delivered in a 250-l volume with 50 g
protein subcutaneously in each thigh during each of the two protein boosts. All animals were challenged
at week 20 following the final protein immunization with a 1:4 dilution of SHIV.C.CH505 (stock at
189 ng/ml), obtained from George Shaw and Nancy Miller. The virus was diluted 1:4 in RPMI 1640 to
obtain a challenge volume of 1 ml. Animals were positioned in a prone position, and a 1-ml syringe
without a needle was used to inoculate the virus. Animals were challenged weekly, with 8 repeat doses,
or until virus was detected in plasma.
Adjuvants. Dimyristoyl phosphatidylcholine (DMPC) and dimyristoyl phosphatidylglycerol (DMPG)
saturated phospholipids, cholesterol (Chol), synthetic monophosphoryl lipid A (MPLA), and 3-deacyl
monophosphoryl hexa-acyl lipid A (3D-PHAD) (Avanti Polar Lipids) were used as adjuvants. DMPC and
Chol were dissolved in chloroform, and DMPG and MPLA were dissolved in chloroform-methanol (9:1).
aluminum hydroxide (AH) (Alhydrogel) in a gel suspension was purchased from Brenntag. The QS-21
saponin was purchased from Desert King International and was dissolved in Sorensen phosphate-
buffered saline (PBS) (pH 5.6).
Army liposome formulations (ALFs) containing DMPC, DMPG, Chol, and MPLA were prepared by
the lipid deposition method. For vaccine preparations adjuvanted with ALFA, dissolved lipids were
mixed in a molar ratio of 9:1:7.5:0.36 (DMPC to DMPG to Chol to MPLA) and dried by rotary
evaporation followed by overnight desiccation. Liposomes were formed by using molecular-biology-
grade water (Quality Biological), microfluidized, and sterile filtered, followed by lyophilization. One
hundred micrograms of gp140 protein was adsorbed to 600 g of Alhydrogel in PBS (pH 7.4) and
incubated on a tilted roller at room temperature (RT) for 1 h prior to addition to lyophilized ALF. For
vaccine preparations adjuvanted with ALFQ (ALF containing QS-21), lipids were mixed in a molar
ratio of 9:1:12.2:0.36 (DMPC to DMPG to Chol to MPLA), dried, and rehydrated by adding Sorensen
PBS (pH 6.2), followed by microfluidization and filtration. gp140 was mixed with ALFQ in a 1:1
volumetric ratio. Each vaccine dose in a 500-l volume contained 100 g MPLA (and 100 g protein)
and either 600 g aluminum or 50 g QS-21.
Specimen collection and processing. Lymph node (LN) biopsy specimens were obtained 2 weeks
following each of the protein boosts and manually processed by disassociation through 100-m cell
strainers and washing in complete medium, as described previously (12). Two weeks after the 3rd DNA
immunization, fine-needle aspirates of LNs were obtained using a 22-gauge needle, as previously
described (65). PBMCs were isolated from whole blood collected in cell preparation tube (CPT) vacutainer
tubes by density gradient centrifugation as previously described (12). For serum, coagulated blood
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was centrifuged at 800  g for 10 min to pellet clotted cells, followed by extraction of fluid and
storage at 80°C. Rectal and vaginal secretions were collected using premoistened Weck-Cel
sponges and eluted as described previously (66).
Serum IgG ELISA. Serum IgG titers against HIV-1 C.1086 Env gp140 and Gag (SIVmac239) were
determined by an ELISA. In brief, 96-well microtiter plates with a high binding capacity (Thermo Fisher)
were coated overnight at 4°C with 1 g/ml C.1086 Env gp140C from the NIH AIDS Reagent Program
(ARP) or with SIVmac239 Gag (Immune Tech) diluted in 0.1 M carbonate-bicarbonate buffer (pH 9.2).
Plates were washed with PBS containing 0.1% Tween 20 (PBST) and blocked with 5% (wt/vol) nonfat dry
milk in PBS for 2 h at RT, followed by four washes with PBST. The standard (PG9 monoclonal antibody
from the ARP) and serum samples were run at 3 dilutions/sample (1:50 to 1:450) in sample dilution buffer
and incubated at RT for 2 h on a microplate shaker. After washing, the plate was incubated for 1 h with
a 1:10,000 dilution of horseradish peroxidase (HRP)-conjugated goat anti-monkey IgG (Nordic MUbio).
The plates were washed and then developed with 3,3=,5,5=-tetramethylbenzidine (TMB) substrate
(Thermo Fisher), and the reaction was quenched with 2 N H2SO4 (Sigma). The absorbance was recorded
at 450 nm with a reference filter at 570 nm using a Spectramax 5 plate reader (Molecular Devices).
Baseline serum samples from each animal served as negative controls, and optical density (OD) values
2-fold above the baseline were considered positive and extrapolated to determine anti-Env antibody
concentrations.
Sodium thiocyanate avidity assay. C.1086 Env gp140C-specific IgG antibody avidity was deter-
mined using a chaotropic displacement ELISA with sodium thiocyanate (NaSCN). Serum samples were
incubated in duplicate at 6,000 pg per well for 2 h at RT. The plate was washed five times. For the
dissociation step, one well of each sample was manually treated with 100 l of 2 M NaSCN (Sigma-
Aldrich) to dissociate antigen-antibody complexes, and a second well of the same sample was treated
with PBS as a control. The plate was incubated for 15 min at RT, followed by washing three times. The
plate was then developed as described above for the C.1086 gp140C ELISA. For each sample, antibody
avidity was reported as an avidity index (AI) value (a percentage), which was calculated as the ratio of
the absorbance in the well treated with NaSCN to that in the well treated with PBS.
Biacore binding and avidity analysis. Binding and avidity determinations were conducted using
the Biacore 4000 surface plasmon resonance (SPR) system. The immobilizations were performed in a
solution containing 10 mM HEPES and 150 mM NaCl (pH 7.4) using a standard amine-coupling kit, as
previously described (23, 67). The CM5-S series chip surface was activated with a 1:1 mixture of 0.4 M
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 0.1 M N-hydroxysuccinimide
(NHS) for 600 s (GE Healthcare). For the cyclic biotinylated V2 C.1086 peptide, 1 M streptavidin (Life
Technologies) in 10 mM sodium acetate (pH 4.5) (5,800 to 7,400 RU) was coupled for 720 s. The
immobilized surface was then deactivated with 1.0 M ethanolamine-HCl (pH 8.5) for 600 s. Spot 3 in each
flow cell was left unmodified to serve as a reference. Following surface deactivation, 0.06 to 1.5 M cyclic
biotinylated V2 C.1086 peptide was captured, resulting in two ranges of densities: high density (1,900 to
2,300 RU) and low/medium density (340 to 580 RU). For C.1086 gp140C, 0.56 to 15 g/ml protein was
immobilized directly on the CM5 sensor chip, resulting in four ranges of densities: very high density
(9,800 to 10,100 RU), high density (3,400 to 4,100 RU), medium density (960 to 1,700 RU), and low density
(240 to 670 RU). Following surface preparation, heat-inactivated serum samples were diluted 1:50 in
running buffer (10 mM HEPES, 300 mM NaCl, and 0.005% Tween 20 [pH 7.4]). The diluted samples were
injected onto the V2 peptide or gp140 protein surface for 320 s, followed by an 1,800-s dissociation
period. The bound surface was then enhanced with a 240-s injection of 30 g/ml of the secondary
antibody goat anti-monkey IgG. To regenerate the bound surface, 175 mM HCl was injected for 70 s. For
each serum sample or controls, 4 to 8 replicates were collected at a rate of 10 Hz, with an analysis
temperature of 25°C. All sample injections were conducted at a flow rate of 10 l/min. Data analysis was
performed using Biacore 4000 Evaluation software 4.1 with double subtractions for an unmodified
surface and buffer for the blank. Fitting was conducted using the dissociation mode integrated with
Evaluation software 4.1.
Binding antibody multiplex assay and sodium citrate avidity assay. An HIV-specific serum IgG
binding antibody multiplex assay (BAMA) was performed as previously described (68) with a panel
of Env and V1V2 antigens: C.1086 gp140, CH505 T/F gp140, Con S (group M consensus) gp140, Con
C (clade C consensus) gp140, and gp70-V1V2 clade B/Case A2 scaffolded protein. Samples were
titrated in 5-fold serial dilutions starting at 1:80, and the binding magnitude is reported as the AUC.
Positivity criteria (determined at a dilution of 1:80) were as follows: (i) a mean fluorescence intensity
(MFI) of 100, (ii) an MFI higher than the Ag-specific cutoff (95th percentile of all baseline binding
per antigen), and (iii) an MFI 3-fold higher than that of the matched baseline before and after
blank/MLV subtraction. All BAMAs and avidity assays were performed in a blind fashion using
magnetic beads. For avidity assays, samples were tested with and without sodium citrate (0.1 M, pH
3.0) at 2 dilutions for each antigen based on BAMA titration for maximum coverage of samples in
the linear range of the assay. The dilutions were 1:80 and 1:400 for gp70-V1V2, 1:400 for C.1086
V1V2, 1:2,000 for CH505 T/F gp140, 1:2,000 for Con C gp140, and 1:10,000 for C.1086 gp140 and Con
S gp140. Antibody avidity is reported as an avidity index, which was calculated as 100  (MFI in the
citrate-treated well/MFI in the untreated well). The avidity index is reported for sample-antigen
combinations that were (i) identified as positive responders in the IgG BAMA and (ii) had an MFI
within the linear range for the untreated sample.
Neutralization. Neutralization assays were performed as previously described (69) using TZM-bl
cells. We measured neutralization activity against the tier 1 clade C pseudovirus MW965.26 using
MLV-pseudotyped virus as an indicator of non-HIV-specific activity in the assay. Neutralization titers
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were measured at week 2 and week 8 after the 2nd protein boost and were considered to be positive
for neutralizing antibody activity based on the criterion of a signal of 3 detected against the MLV
negative-control virus. The majority of positive titers detected were against the tier 1 virus
MW965.26, with occasional very weak neutralization titers against the tier 2 C.1086_B2 and SHIV
CH505.375H viruses.
Antibody-dependent cellular cytotoxicity. The rhesus CD16 human KHYG-1 NK cell line (effector
cells) and CEM.NKR-CCR5-sLTR-Luc cell line (target cells) were provided by David Evans (University of
Wisconsin) and were maintained in R10 culture medium consisting of RPMI 1640 supplemented with 10%
fetal bovine serum, 25 mM HEPES, 2 mM L-glutamine, and 0.1 mg/ml Primocin (70, 71). The R10 medium
for CD16 KHYG-1 cells was additionally supplemented with cyclosporine (CsA) and interleukin-2 (IL-2)
at concentrations of 1 g/ml and 5 U/ml, respectively.
Luciferase-based ADCC assays were carried out as previously described, with some modifications (70).
Two million CEM.NKR-CCR5-sLTR-Luc target cells were spinoculated with SHIV.C.CH505.375H.dCT (38 ng
p27) for 2 h at 2,600 rpm at 30°C in the presence of 10 g/ml Polybrene. Subsequently, the target
cell-virus mixture was incubated overnight at 37°C with 5% CO2. The next day, virus was removed, and
cells were incubated for another 72 h prior to the ADCC assay. For the ADCC assay, serum, effector cells,
and target cells were plated in a 1:1:1 volumetric ratio. Serum was heat inactivated, diluted (1:50 dilution
in R10 medium containing 10 U IL-2 per ml, with no CsA), and mixed with PBS-washed, infected target
cells (1 104 cells per well) and effector cells (5 104 cells per well). Serum and cells were incubated
overnight at 37°C in 5% CO2. Plates were then centrifuged at 1,800 rpm for 5 min at room temperature,
and 100 l of the supernatant was removed. The cell pellets were resuspended and mixed with 50 l of
the luciferase substrate reagent BriteLite Plus (PerkinElmer). Relative light units (RLUs) were recorded in
black 96-well plates according to the manufacturer’s instructions, using a Synergy 2 microplate lumi-
nometer (BioTek). The percent ADCC activity of each tested serum sample (week 2 and week 8 after the
2nd protein immunization) was measured as the reduction in RLU compared to the animal’s week 0
preimmune serum (100% RLU). All samples were tested in triplicate, and experiments were performed
twice.
Antibody-dependent phagocytosis. Serum antibodies were tested for their ability to enhance the
phagocytosis of gp120-expressing beads by THP-1 cells using methods similar to those previously
described (69). Briefly, 5 l of 1-m avidin-coated fluorospheres (Invitrogen) was labeled with 2 g
biotinylated anti-His tag antibody (Pierce) and then 3.5 g His-tagged clade C gp120 Du151 protein
(Immune Technologies) per plate. The gp120 beads and triplicate 5-fold dilutions of heat-inactivated
serum in a 50-l volume were then preincubated at 37°C in V-bottom plates. After 1 h, 2 104 THP-1
cells in 50 l were added to each well. After 5 h at 37°C in 5% CO2, the cells were washed in Ca2- and
Mg2-free Dulbecco’s PBS (DPBS) and resuspended in 180 l of warm 0.12% trypsin-EDTA. After 5 min
at 37°C, the trypsin was removed, and the cells were resuspended in 1% paraformaldehyde. Fluorescence
was evaluated using a FACSCanto instrument (BD Biosciences) and FlowJo software. Phagocytosis was
measured by multiplying the percent fluorescent cells by their median fluorescence intensity. The
phagocytic score was then calculated by dividing the phagocytosis of test samples by the average
phagocytosis measured with preimmune serum.
IgG subclass antibodies. Ten rows of a 96-well Immulon 4 microtiter plate (VWR) were coated
overnight at 4°C with 50 ng per well of C.1086 gp120 Δ7 K160N protein (72) in PBS. The remaining
2 rows were coated with duplicate 2-fold serial dilutions of rhesus IgG1, IgG2, IgG3, or IgG4
(Nonhuman Primate Reagent Program) starting at 25 ng/ml in PBS to generate a standard curve.
Plates were washed with PBS containing 0.05% Tween 20 and blocked for 30 min at RT with reagent
buffer (0.1% bovine serum albumin in wash buffer). Twofold or 3-fold dilutions of serum in reagent
buffer were then added to the wells coated with gp120. Reagent buffer was added to wells coated
with the standard. Following overnight storage at 4°C, the plate was washed and reacted for 1 h at
37°C with 1 g/ml of the relevant monoclonal antibody from the Nonhuman Primate Reagent
Resource: anti-rhesus IgG1 (mouse IgG2a clone 3C10.3), anti-rhesus IgG2 (mouse IgG1 clone 3C10),
anti-rhesus IgG3 (mouse IgG1 clone 2G11), or anti-rhesus IgG4 (mouse IgG1 clone 7A8). These
antibodies were raised to react specifically with the respective rhesus IgG subclasses and show
negligible reactivity with other subclasses, and the specificity of 7A8 was further confirmed in our
laboratory. The plate was then consecutively washed and treated with 100 ng/ml of biotinylated
goat anti-mouse IgG1 or IgG2a for 1 h at 37°C, Neutralite-avidin peroxidase for 30 min at RT, and TMB
(all from SouthernBiotech). The absorbance was recorded at 370 nm. SoftMax Pro software (Molec-
ular Devices) was used to construct a standard curve and determine concentrations of antibody.
Preimmune serum samples had 10 ng/ml of antibody in these assays.
Mucosal antibodies and serum IgA. A BAMA with C.1086 gp140 K160N-labeled magnetic beads
(MagPlex; Bio-Rad) was used as previously described (72) to measure concentrations of antigen-specific
IgG in secretions and IgA in both secretions and serum depleted of IgG. Briefly, beads reacted with
dilutions of the standard (73) and specimens at 1,100 rpm at 4°C overnight were washed and developed
with biotinylated anti-monkey IgG or -monkey IgA (Rockland) followed by phycoerythrin-labeled
Neutralite-avidin (SouthernBiotech). The construction of standard curves and interpolation of antibody
concentrations were done using Bioplex Manager software after measurement of fluorescence with a
Bioplex 200 instrument (Bio-Rad). Concentrations of gp120-specific IgG or IgA in secretions were divided
by the total IgG or IgA measured in the sample by an ELISA (74) to obtain the specific activity (nanograms
of IgG or IgA antibody per microgram of total IgG or IgA).
Activation-induced marker assay. Cells were stimulated with overlapping peptide pools of HIV
consensus C and HIV-1 C.1086 Env gp140C proteins and SIVmac239 Gag in activation-induced marker
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(AIM) medium as previously described (30). All antigens were used at a final concentration of 2 g/ml
in a stimulation cocktail made using 0.2 g of CD28 and 0.2 g of CD49d costimulatory antibodies per
test. Unstimulated controls were treated with volume-controlled dimethyl sulfoxide (DMSO) (Sigma-
Aldrich). Tubes were incubated in 5% CO2 at 37°C overnight. Following an 18-h stimulation, the cells were
stained, fixed, and acquired the same day. A phenotype panel on LNs and PBMCs was performed using
standard flow cytometry assays (12).
Serum cytokines. A Legendplex assay (BioLegend) was performed to evaluate cytokines in rhesus
macaque sera. The assay was performed according to the manufacturer’s protocol. Samples were
acquired on a BD LSR Fortessa cell analyzer.
Flow cytometry and cell sorting. Cell staining and sorting were performed as previously described
(12). Fluorescence was measured using a BD FACSymphony cell analyzer with FACSDiva version 8.0.1
software. Compensation, gating, and analysis were performed using FlowJo (versions 9 and 10). Cell
sorting was performed using a BD FACSAria III cell sorter. Reagents used for flow cytometry are listed in
Table 1.
RNA sequencing and bioinformatics. RNA was extracted from sorted subsets, and DNA-free RNA was
quantified and assessed for quality prior to sequencing. RNA samples with visible peaks, a 260/280 absor-
bance ratio of between 1.8 and 2.1, and an RNA integrity number of 7 were sequenced using 3= Tag-Seq
gene expression profiling on the Illumina HiSeq sequencer at the DNA Technologies and Expression Analysis
Core Laboratory at the UC Davis Genome Center. Samples were barcoded and run in a single HiSeq lane. The
quality of data was verified using the Illumina SAV viewer; this included verifying low error rates based on
alignments of the standard Illumina PhiX spike and removal of PCR duplicates after alignments. Adapter
trimming, quality control (QC) of sequencing data, and demultiplexing were performed by the UC Davis
Bioinformatics Core. After read filtering, reads were mapped to a reference genome using HISAT-aligner. On
average, 82.17% of reads were mapped (55 to 61% uniquely mapped), and the uniformity of the mapping
result for each sample indicated comparability between samples. Prior to differential gene expression analysis,
genes with fewer than 40 counts per million reads were filtered, leaving 7,086 genes. Differential expression
analyses were conducted using the limma-voom Bioconductor pipeline (32).
Statistical analysis. Statistical analysis was performed using GraphPad Prism 7. Results between
groups were compared using the two-tailed nonparametric Mann-Whitney rank sum test. Within-group
comparisons, such as antibody levels at different time points, were done using the two-tailed Wilcoxon
matched-pairs signed-rank test. For correlation analysis, the two-tailed Spearman rank correlation test
was used.
Data availability. The data discussed in this publication have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through GEO Series accession number GSE141707.
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